EMS
São Paulo, Brazil· Est.
Brazil's top generic and specialty drug manufacturer with a robust biosimilar pipeline and pan‑Latin America distribution.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $500M
AI Company Overview
Brazil's top generic and specialty drug manufacturer with a robust biosimilar pipeline and pan‑Latin America distribution.
OncologyImmunologyCardiologyInfectious DiseasesCentral Nervous SystemDermatology
Technology Platform
Advanced solid‑dose formulation and aseptic bioprocessing platforms enabling high‑volume generic drug production and cost‑effective biosimilar development.
Opportunities
Expansion of biosimilar portfolio into high‑growth markets and leveraging its large distribution network to capture emerging specialty drug segments.
Risk Factors
Regulatory delays for biologics, currency fluctuations affecting import‑export margins, and intense competition from regional and global generics firms.
Competitive Landscape
EMS competes with Eurofarma, Aché, and multinational generics giants; its differentiation lies in integrated manufacturing, strong local market share, and a growing biosimilar pipeline.